Get access to this article and to all of thebmj.com for 14 daysSign up today for a 14 day free trial

India’s Intellectual Property Appellate Board has repealed the patent granted to the drug company Roche for pegylated interferon alfa-2a (Pegasys), which is used to treat hepatitis C.

The board’s order represents a watershed in the history of patents in India and a victory for patients’ groups fighting to widen access to drugs.

“This is India’s first successful post-grant opposition case,” said Eldred Tellis, director of the Sankalp Rehabilitation Trust, a non-governmental organisation that had challenged the patent. “And it is significant because the patent granted to Roche in 2006 was the first product patent on a medicine in India after …

Get access to this article and to all of thebmj.com for 14 daysSign up today for a 14 day free trial